A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Name: A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Published: 2022
License: Public Domain

Hellenic Society of Hematology · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

multiple-myeloma neoplasms

multiple myeloma, renal impairment, neoplasms, plasma cell, neoplasms by histologic type, neoplasms, paraproteinemias, blood protein disorders, hematologic diseases, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Related documents